FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Merus N.V. Stock AnalysisComprehensive stock analysis for Merus N.V. (MRUS) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisMRUS
MRUS
Merus N.V.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
MRUS
Home🔹Stocks🔹Merus N.V.

Merus N.V.

MRUS•NASDAQ

Merus N.V.

MRUS•NASDAQ
Market cap
$6.83B
Sentiment

Your view on MRUS

Mkt Cap
$6.83B
Sentiment
Your view
MRUS
Merus N.V.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
MRUS
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Merus N.V.

Industry
Biotechnology
Sector
Healthcare
CEO
Sven Ante Lundberg
Headquarters
Yalelaan 62, Utrecht, NL
Industry
Biotechnology
Sector
Healthcare
CEO
Sven Ante Lundberg
Headquarters
Yalelaan 62, Utrecht, NL
Description

Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

Infographics

Visual summary of the business at a glance.

FRC Research

Media

Videos and interviews covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Peer Comparison

Comparables

List of peer companies in the same industry.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Insider Trading

Recent buying and selling by company executives.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

News

Latest headlines and market coverage.

News

Latest Market News